Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(625)
•••
Comment by KayakerBCon Dec 04, 2017 1:06pm
147 Views
Post# 27086111

RE:RE:Trading Halt

RE:RE:Trading HaltDigitel posted....

Interesting how Stockwatch titled the news release:
Bioasis Technologies has three directors resign   
2017-12-04 10:14 ET - News Release
Dr. Mark Day reports
BIOASIS IMPLEMENTS TRANSITION PLAN FOR ITS BOARD OF DIRECTORS
Rob Hutchison and Michael Hutchison have submitted their planned resignations from the board. Ron Erickson has also resigned from the board.....

What's so interesting?  Stockhouse titled it the same as the company's press release.  It looks like you trying to suggest that Stockhouse added this: "Bioasis Technologies has three directors resign".  If so, how about a link.

From Stockhouse:

Bioasis Implements Transition Plan for Its Board of Directors
V.BTI | 4 hours ago
Bioasis Implements Transition Plan for Its Board of Directors

Company intends to selectively replace outgoing directors with new, highly qualified, independent candidates

BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company focused on the delivery of....

stockhouse

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities